image

PRT1419

Prelude is developing PRT1419, which is designed to be a potent and selective inhibitor of MCL1.

Prelude is developing PRT1419, which is designed to be a potent and selective inhibitor of MCL1. An intravenous formulation (IV) is being evaluated in a Phase 1 clinical trial in patients with solid tumors.  Prelude has prioritized development of the IV formulation, which has demonstrated a desirable pharmacokinetic, pharmacodynamic and safety profile with potential for differentiation from competitor compounds in development.  Prelude intends to initiate a combination trial with venetoclax by mid-year 2022, with the goal of establishing safety, clinical activity and a recommended Phase 2 dose by 2H/2022.

MCL1 Graphic 2